\relax 
\providecommand\hyper@newdestlabel[2]{}
\providecommand\HyperFirstAtBeginDocument{\AtBeginDocument}
\HyperFirstAtBeginDocument{\ifx\hyper@anchor\@undefined
\global\let\oldcontentsline\contentsline
\gdef\contentsline#1#2#3#4{\oldcontentsline{#1}{#2}{#3}}
\global\let\oldnewlabel\newlabel
\gdef\newlabel#1#2{\newlabelxx{#1}#2}
\gdef\newlabelxx#1#2#3#4#5#6{\oldnewlabel{#1}{{#2}{#3}}}
\AtEndDocument{\ifx\hyper@anchor\@undefined
\let\contentsline\oldcontentsline
\let\newlabel\oldnewlabel
\fi}
\fi}
\global\let\hyper@last\relax 
\gdef\HyperFirstAtBeginDocument#1{#1}
\providecommand\HyField@AuxAddToFields[1]{}
\providecommand\HyField@AuxAddToCoFields[2]{}
\citation{ribas2018cancer}
\citation{topalian2015immune}
\citation{sharma2017primary}
\citation{yarchoan2017tumor}
\citation{patel2015pd}
\citation{samstein2019tumor}
\citation{stratigos2021european}
\citation{migden2018pd}
\citation{bonilla2016genomic}
\citation{davis1988t,rossjohn2015t}
\citation{robins2009comprehensive}
\citation{glanville2017identifying}
\citation{dash2017quantifiable}
\citation{zhang2018investigation}
\citation{robins2009comprehensive,mamedov2013preparing}
\citation{tumeh2014pd}
\citation{postow2015peripheral}
\@writefile{toc}{\contentsline {section}{\numberline {1}Introduction}{3}{section.1}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {1.1}Cancer Immunotherapy and Predictive Biomarkers}{3}{subsection.1.1}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {1.2}T-Cell Receptor Biology and Repertoire Analysis}{3}{subsection.1.2}\protected@file@percent }
\citation{greiff2015bioinformatic}
\citation{lecun2015deep}
\citation{dietterich1997solving}
\citation{ilse2018attention}
\citation{vaswani2017attention}
\citation{bahdanau2015neural}
\citation{sidhom2021deeptcr}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.3}Deep Learning for TCR Repertoire Classification}{4}{subsection.1.3}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {1.4}Study Objectives}{4}{subsection.1.4}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {2}Methods}{5}{section.2}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {2.1}Study Design and Patient Cohort}{5}{subsection.2.1}\protected@file@percent }
\@writefile{lot}{\contentsline {table}{\numberline {1}{\ignorespaces \textbf  {Patient and Repertoire Characteristics}\relax }}{5}{table.caption.2}\protected@file@percent }
\providecommand*\caption@xref[2]{\@setref\relax\@undefined{#1}}
\newlabel{tab:patient_characteristics}{{1}{5}{\textbf {Patient and Repertoire Characteristics}\relax }{table.caption.2}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.2}TCR Sequencing and Data Processing}{5}{subsection.2.2}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {1}{\ignorespaces \textbf  {Data Processing Pipeline.} Overview of the complete analytical workflow from raw TCR sequencing data through quality control, feature encoding, and DeepTCR model training. The pipeline processed 239,637 productive TRB sequences from 34 patients for analysis.\relax }}{6}{figure.caption.3}\protected@file@percent }
\newlabel{fig:pipeline}{{1}{6}{\textbf {Data Processing Pipeline.} Overview of the complete analytical workflow from raw TCR sequencing data through quality control, feature encoding, and DeepTCR model training. The pipeline processed 239,637 productive TRB sequences from 34 patients for analysis.\relax }{figure.caption.3}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.3}Feature Engineering and Encoding}{6}{subsection.2.3}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {2.4}DeepTCR Architecture}{6}{subsection.2.4}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {2}{\ignorespaces \textbf  {DeepTCR Model Architecture.} The attention-based multiple instance learning framework processes individual TCR sequences through a convolutional encoder, integrates gene usage features, applies learned attention weights to identify important sequences, and aggregates to patient-level predictions.\relax }}{7}{figure.caption.4}\protected@file@percent }
\newlabel{fig:architecture}{{2}{7}{\textbf {DeepTCR Model Architecture.} The attention-based multiple instance learning framework processes individual TCR sequences through a convolutional encoder, integrates gene usage features, applies learned attention weights to identify important sequences, and aggregates to patient-level predictions.\relax }{figure.caption.4}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.5}Training Configuration}{7}{subsection.2.5}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {2.6}Monte Carlo Cross-Validation}{7}{subsection.2.6}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {2.7}Statistical Analysis}{8}{subsection.2.7}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {3}Results}{8}{section.3}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {3.1}Cohort Characteristics}{8}{subsection.3.1}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {3}{\ignorespaces \textbf  {Cohort Overview.} (A) Distribution of TCR sequences per patient by response status. (B) CDR3 length distribution across the cohort. (C) Summary of key cohort characteristics.\relax }}{9}{figure.caption.5}\protected@file@percent }
\newlabel{fig:cohort}{{3}{9}{\textbf {Cohort Overview.} (A) Distribution of TCR sequences per patient by response status. (B) CDR3 length distribution across the cohort. (C) Summary of key cohort characteristics.\relax }{figure.caption.5}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.2}Model Performance}{9}{subsection.3.2}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {4}{\ignorespaces \textbf  {Model Performance.} (A) Receiver operating characteristic (ROC) curve showing mean performance (solid line) with 95\% confidence band (shaded region) across 100 cross-validation folds. (B) Distribution of AUC values across folds, demonstrating consistent performance. (C) Summary statistics table.\relax }}{10}{figure.caption.6}\protected@file@percent }
\newlabel{fig:performance}{{4}{10}{\textbf {Model Performance.} (A) Receiver operating characteristic (ROC) curve showing mean performance (solid line) with 95\% confidence band (shaded region) across 100 cross-validation folds. (B) Distribution of AUC values across folds, demonstrating consistent performance. (C) Summary statistics table.\relax }{figure.caption.6}{}}
\@writefile{lot}{\contentsline {table}{\numberline {2}{\ignorespaces \textbf  {Model Performance Summary}\relax }}{10}{table.caption.7}\protected@file@percent }
\newlabel{tab:performance}{{2}{10}{\textbf {Model Performance Summary}\relax }{table.caption.7}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.3}Training Dynamics}{10}{subsection.3.3}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {5}{\ignorespaces \textbf  {Training Dynamics.} (A) Loss curves across training epochs showing convergence. (B) AUC progression during training. (C) Computational performance metrics.\relax }}{11}{figure.caption.8}\protected@file@percent }
\newlabel{fig:training}{{5}{11}{\textbf {Training Dynamics.} (A) Loss curves across training epochs showing convergence. (B) AUC progression during training. (C) Computational performance metrics.\relax }{figure.caption.8}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.4}Attention Analysis}{11}{subsection.3.4}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {6}{\ignorespaces \textbf  {Attention Analysis.} (A) Distribution of attention weights by response group showing responders (green) have distinct attention patterns compared to non-responders (red). (B) Comparison of mean attention weights per patient. (C) Statistical comparison with Mann-Whitney U test results. Complete attention weight distribution is provided in Figure\nobreakspace  {}\ref  {fig:s5}.\relax }}{12}{figure.caption.9}\protected@file@percent }
\newlabel{fig:attention}{{6}{12}{\textbf {Attention Analysis.} (A) Distribution of attention weights by response group showing responders (green) have distinct attention patterns compared to non-responders (red). (B) Comparison of mean attention weights per patient. (C) Statistical comparison with Mann-Whitney U test results. Complete attention weight distribution is provided in Figure~\ref {fig:s5}.\relax }{figure.caption.9}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.5}Gene Usage Patterns}{12}{subsection.3.5}\protected@file@percent }
\@writefile{lof}{\contentsline {figure}{\numberline {7}{\ignorespaces \textbf  {Gene Usage Patterns.} (A) V-gene usage frequency by response status. (B) J-gene usage frequency by response status. (C) V-J pairing preferences in responders vs. non-responders.\relax }}{13}{figure.caption.10}\protected@file@percent }
\newlabel{fig:gene_usage}{{7}{13}{\textbf {Gene Usage Patterns.} (A) V-gene usage frequency by response status. (B) J-gene usage frequency by response status. (C) V-J pairing preferences in responders vs. non-responders.\relax }{figure.caption.10}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.6}Top Predictive Sequences}{13}{subsection.3.6}\protected@file@percent }
\@writefile{lot}{\contentsline {table}{\numberline {3}{\ignorespaces \textbf  {Top 10 Predictive TCR Sequences by Attention Weight}\relax }}{14}{table.caption.11}\protected@file@percent }
\newlabel{tab:top_sequences}{{3}{14}{\textbf {Top 10 Predictive TCR Sequences by Attention Weight}\relax }{table.caption.11}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.7}Sequence Characteristics}{14}{subsection.3.7}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {4}Discussion}{14}{section.4}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {4.1}Principal Findings}{14}{subsection.4.1}\protected@file@percent }
\citation{patel2015pd}
\citation{samstein2019tumor}
\citation{tumeh2014pd}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.2}Comparison with Existing Biomarkers}{15}{subsection.4.2}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {4.3}Biological Implications}{15}{subsection.4.3}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {4.4}Limitations}{15}{subsection.4.4}\protected@file@percent }
\@writefile{toc}{\contentsline {subsection}{\numberline {4.5}Future Directions}{16}{subsection.4.5}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{\numberline {5}Conclusion}{16}{section.5}\protected@file@percent }
\citation{anthropic2025claudecode}
\citation{chen2021codex}
\citation{sidhom2021deeptcr}
\bibstyle{plainnat}
\bibdata{references}
\bibcite{anthropic2025claudecode}{{1}{2025}{{Anthropic}}{{}}}
\bibcite{bahdanau2015neural}{{2}{2015}{{Bahdanau et~al.}}{{Bahdanau, Cho, and Bengio}}}
\bibcite{bonilla2016genomic}{{3}{2016}{{Bonilla et~al.}}{{Bonilla, Parmentier, King, Bezrukov, Kber, Stuber, Letourneau, Sima, Radi, Pereira, et~al.}}}
\bibcite{chen2021codex}{{4}{2021}{{Chen et~al.}}{{Chen, Tworek, Jun, Yuan, de~Oliveira~Pinto, Kaplan, Edwards, Burda, Joseph, Brockman, et~al.}}}
\bibcite{dash2017quantifiable}{{5}{2017}{{Dash et~al.}}{{Dash, Fiore-Gartland, Hertz, Wang, Sharma, Souquette, Crawford, Clemens, Nguyen, Kedzierska, et~al.}}}
\bibcite{davis1988t}{{6}{1988}{{Davis and Bjorkman}}{{}}}
\bibcite{dietterich1997solving}{{7}{1997}{{Dietterich et~al.}}{{Dietterich, Lathrop, and Lozano-P{\'e}rez}}}
\bibcite{glanville2017identifying}{{8}{2017}{{Glanville et~al.}}{{Glanville, Huang, Nau, Hatton, Wagar, Rubelt, Ji, Han, Krams, Pettus, et~al.}}}
\bibcite{greiff2015bioinformatic}{{9}{2015}{{Greiff et~al.}}{{Greiff, Miho, Menzel, and Reddy}}}
\bibcite{ilse2018attention}{{10}{2018}{{Ilse et~al.}}{{Ilse, Tomczak, and Welling}}}
\bibcite{lecun2015deep}{{11}{2015}{{LeCun et~al.}}{{LeCun, Bengio, and Hinton}}}
\bibcite{mamedov2013preparing}{{12}{2013}{{Mamedov et~al.}}{{Mamedov, Britanova, Zvyagin, Turchaninova, Bolotin, Putintseva, Lebedev, and Chudakov}}}
\bibcite{migden2018pd}{{13}{2018}{{Migden et~al.}}{{Migden, Rischin, Schmults, Guminski, Hauschild, Lewis, Chung, Hernandez-Aya, Lim, Chang, et~al.}}}
\bibcite{patel2015pd}{{14}{2015}{{Patel and Kurzrock}}{{}}}
\bibcite{postow2015peripheral}{{15}{2015}{{Postow et~al.}}{{Postow, Manuel, Wong, Yuan, Dong, Liu, Perez, Tanneau, Noel, Courtier, et~al.}}}
\bibcite{ribas2018cancer}{{16}{2018}{{Ribas and Wolchok}}{{}}}
\bibcite{robins2009comprehensive}{{17}{2009}{{Robins et~al.}}{{Robins, Campregher, Srivastava, Wacher, Turtle, Kahsai, Riddell, Warren, and Carlson}}}
\bibcite{rossjohn2015t}{{18}{2015}{{Rossjohn et~al.}}{{Rossjohn, Gras, Miles, Turner, Godfrey, and McCluskey}}}
\bibcite{samstein2019tumor}{{19}{2019}{{Samstein et~al.}}{{Samstein, Lee, Shoushtari, Hellmann, Shen, Janjigian, Barron, Zehir, Jordan, Omuro, et~al.}}}
\bibcite{sharma2017primary}{{20}{2017}{{Sharma et~al.}}{{Sharma, Hu-Lieskovan, Wargo, and Ribas}}}
\bibcite{sidhom2021deeptcr}{{21}{2021}{{Sidhom et~al.}}{{Sidhom, Larman, Pardoll, and Baras}}}
\bibcite{stratigos2021european}{{22}{2020}{{Stratigos et~al.}}{{Stratigos, Garbe, Dessinioti, Lebbe, Bataille, Bastholt, Dreno, Fargnoli, Forsea, Frenard, et~al.}}}
\bibcite{topalian2015immune}{{23}{2015}{{Topalian et~al.}}{{Topalian, Drake, and Pardoll}}}
\bibcite{tumeh2014pd}{{24}{2014}{{Tumeh et~al.}}{{Tumeh, Harview, Yearley, Shintaku, Taylor, Robert, Chmielowski, Spasic, Henry, Ciobanu, et~al.}}}
\bibcite{vaswani2017attention}{{25}{2017}{{Vaswani et~al.}}{{Vaswani, Shazeer, Parmar, Uszkoreit, Jones, Gomez, Kaiser, and Polosukhin}}}
\bibcite{yarchoan2017tumor}{{26}{2017}{{Yarchoan et~al.}}{{Yarchoan, Hopkins, and Jaffee}}}
\bibcite{zhang2018investigation}{{27}{2020}{{Zhang et~al.}}{{Zhang, Ma, Schonnesen, Zhang, He, Sun, Williams, Jain, Bhattacharya, Fang-Landau, et~al.}}}
\@writefile{lof}{\contentsline {figure}{\numberline {8}{\ignorespaces \textbf  {Detailed AUC Analysis.} (A) Histogram of AUC values across 100 folds. (B) Box plot with individual fold values. (C) Fold-by-fold AUC stability analysis.\relax }}{21}{figure.caption.18}\protected@file@percent }
\newlabel{fig:s1}{{8}{21}{\textbf {Detailed AUC Analysis.} (A) Histogram of AUC values across 100 folds. (B) Box plot with individual fold values. (C) Fold-by-fold AUC stability analysis.\relax }{figure.caption.18}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {9}{\ignorespaces \textbf  {Per-Patient Analysis.} (A) Repertoire size by patient. (B) Prediction confidence by patient. (C) Attention weight distributions across patients.\relax }}{22}{figure.caption.20}\protected@file@percent }
\newlabel{fig:s2}{{9}{22}{\textbf {Per-Patient Analysis.} (A) Repertoire size by patient. (B) Prediction confidence by patient. (C) Attention weight distributions across patients.\relax }{figure.caption.20}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {10}{\ignorespaces \textbf  {J-Gene Usage Analysis.} (A) J-gene frequency comparison between responders and non-responders. (B) J-gene diversity metrics.\relax }}{22}{figure.caption.22}\protected@file@percent }
\newlabel{fig:s3}{{10}{22}{\textbf {J-Gene Usage Analysis.} (A) J-gene frequency comparison between responders and non-responders. (B) J-gene diversity metrics.\relax }{figure.caption.22}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {11}{\ignorespaces \textbf  {Computational Performance.} (A) Training time per fold. (B) GPU memory utilization. (C) Throughput analysis on H100 GPU.\relax }}{23}{figure.caption.24}\protected@file@percent }
\newlabel{fig:s4}{{11}{23}{\textbf {Computational Performance.} (A) Training time per fold. (B) GPU memory utilization. (C) Throughput analysis on H100 GPU.\relax }{figure.caption.24}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {12}{\ignorespaces \textbf  {Attention Weight Distribution.} Complete distribution of attention weights across all 239,634 TCR sequences. The log-scale histogram reveals a highly skewed distribution with most sequences receiving near-zero attention, while a small subset (top 1\%, n=2,379) exhibit high attention weights indicative of predictive importance.\relax }}{23}{figure.caption.26}\protected@file@percent }
\newlabel{fig:s5}{{12}{23}{\textbf {Attention Weight Distribution.} Complete distribution of attention weights across all 239,634 TCR sequences. The log-scale histogram reveals a highly skewed distribution with most sequences receiving near-zero attention, while a small subset (top 1\%, n=2,379) exhibit high attention weights indicative of predictive importance.\relax }{figure.caption.26}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {13}{\ignorespaces \textbf  {Patient-Level Attention Heatmap.} Heatmap visualization of attention weight statistics across 34 patients. Rows represent individual patients, with color intensity indicating mean attention weight. Patients are grouped by response status (responders vs. non-responders).\relax }}{24}{figure.caption.28}\protected@file@percent }
\newlabel{fig:s6}{{13}{24}{\textbf {Patient-Level Attention Heatmap.} Heatmap visualization of attention weight statistics across 34 patients. Rows represent individual patients, with color intensity indicating mean attention weight. Patients are grouped by response status (responders vs. non-responders).\relax }{figure.caption.28}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {14}{\ignorespaces \textbf  {Top Predictive Sequences Analysis.} (A) V-gene enrichment in top 100 high-attention sequences compared to background frequency. (B) J-gene enrichment analysis. (C) Response distribution showing 72\% of top 100 sequences originate from responder patients. (D) CDR3 length comparison between top sequences and overall population.\relax }}{25}{figure.caption.30}\protected@file@percent }
\newlabel{fig:s7}{{14}{25}{\textbf {Top Predictive Sequences Analysis.} (A) V-gene enrichment in top 100 high-attention sequences compared to background frequency. (B) J-gene enrichment analysis. (C) Response distribution showing 72\% of top 100 sequences originate from responder patients. (D) CDR3 length comparison between top sequences and overall population.\relax }{figure.caption.30}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {15}{\ignorespaces \textbf  {Responder vs. Non-Responder Statistical Comparison.} (A) Attention weight distributions by response group with Mann-Whitney U test results ($p < 10^{-178}$). (B) CDR3 length distributions with Kolmogorov-Smirnov test ($p < 10^{-31}$). (C) V-gene usage comparison. (D) High-attention sequence counts by group.\relax }}{26}{figure.caption.32}\protected@file@percent }
\newlabel{fig:s8}{{15}{26}{\textbf {Responder vs. Non-Responder Statistical Comparison.} (A) Attention weight distributions by response group with Mann-Whitney U test results ($p < 10^{-178}$). (B) CDR3 length distributions with Kolmogorov-Smirnov test ($p < 10^{-31}$). (C) V-gene usage comparison. (D) High-attention sequence counts by group.\relax }{figure.caption.32}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {16}{\ignorespaces \textbf  {Sequence Characteristics Analysis.} (A) CDR3 length distribution comparing high-attention vs. low-attention sequences. (B) Amino acid composition enrichment in high-attention sequences. (C) Amino acid property distribution (hydrophobic, polar, charged). (D) Top V-J gene pairings in high-attention sequences.\relax }}{27}{figure.caption.34}\protected@file@percent }
\newlabel{fig:s9}{{16}{27}{\textbf {Sequence Characteristics Analysis.} (A) CDR3 length distribution comparing high-attention vs. low-attention sequences. (B) Amino acid composition enrichment in high-attention sequences. (C) Amino acid property distribution (hydrophobic, polar, charged). (D) Top V-J gene pairings in high-attention sequences.\relax }{figure.caption.34}{}}
\gdef \@abspage@last{27}
